NEWS
12
Mar
2017
Novoheart signs exclusive licensing agreement with the Regents of the University of California for heart cell alignment technologies

Novoheart enters into an exclusive licensing agreement with the Regents of the University of California for technologies developed by Professor Michelle Khine and Professor Ronald Li, scientific co-founders of Novoheart. These inventions allow Novoheart to utilize human pluripotent stem cell-derived heart muscle cells (cardiomyocytes) to produce engineered and aligned cellular platforms, which provide optimal use as drug screening and disease modelling tools.